Related Experiment Video
Updated: Aug 31, 2025
28:13
Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
33.5K
Neuromodulation therapy for atrial fibrillation.
Maham F Karatela1, Marat Fudim1, Joseph P Mathew2
1Cardiac Electrophysiology Section, Duke Heart Center and Department of Medicine, Duke University Medical Center, Durham, North Carolina; Duke Clinical Research Institute, Durham, North Carolina.
Heart Rhythm
|August 21, 2022
Summary
Atrial fibrillation is worsened by both sympathetic and parasympathetic nerves. Therapies targeting the neurocardiac axis show variable efficacy, but evolving understanding promises better treatments for AF.
Area of Science:
- Cardiology
- Neuroscience
- Autonomic Nervous System Research
Background:
- Atrial fibrillation (AF) pathophysiology is complex and influenced by cardiac autonomic innervation.
- Both sympathetic and parasympathetic nervous system activity can promote AF.
- The neurocardiac axis plays a critical role in the development and maintenance of AF.
Purpose of the Study:
- To review innovative therapies targeting the neurocardiac axis for atrial fibrillation.
- To discuss the current understanding of autonomic influences on AF.
- To explore the future of therapeutic neuromodulation for AF management.
Main Methods:
- Review of existing literature on AF pathophysiology and neurocardiac interventions.
- Analysis of therapies including catheter ablation, pharmacologic suppression, renal denervation, vagal stimulation, and stellate ganglion blockade.
- Discussion of the variable efficacy and evolving therapeutic landscape.
Main Results:
- Sympathetic and parasympathetic influences are both profibrillatory in AF.
- Current innovative therapies targeting the neurocardiac axis demonstrate variable efficacy.
- Understanding of the cardiac nervous system in AF is expanding.
Conclusions:
- Therapeutic neuromodulation targeting the neurocardiac axis is a developing field for AF treatment.
- Continued research into the cardiac nervous system will refine AF management strategies.
- Future approaches to neuromodulation hold promise for improving outcomes in patients with AF.
Related Concept Videos
01:25Dysrhythmias VI: Management of Dysrhythmias
104
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
104
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
423
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
423
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
827
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
827
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
493
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
493
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
1.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.7K
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
1.2K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.2K